Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from China NT Pharma Group Co., Ltd. ( (HK:1011) ).
China NT Pharma Group has warned shareholders and investors that it expects to remain loss-making for the year ended 31 December 2025, but forecasts a sharply narrower net loss of about RMB25 million to RMB30 million. This represents a reduction of roughly 44% to 53% from the RMB53.4 million loss recorded in 2024, according to a preliminary review of unaudited accounts.
The improved result is mainly attributed to the absence of a one-off, non-cash fair value loss booked in 2024 and to fair value gains of around RMB14 million on a financial asset tied to its Beijing Kangchen equity interest. The board cautioned that these fair value changes are non-cash, non-core and subject to market volatility, signalling that the better earnings trend may not reflect a sustained improvement in the group’s underlying operating performance ahead of its full results due by end-March 2026.
The most recent analyst rating on (HK:1011) stock is a Hold with a HK$0.76 price target. To see the full list of analyst forecasts on China NT Pharma Group Co., Ltd. stock, see the HK:1011 Stock Forecast page.
More about China NT Pharma Group Co., Ltd.
China NT Pharma Group Co., Ltd. is a Cayman Islands-incorporated pharmaceutical group listed in Hong Kong. The company operates through subsidiaries with a focus on pharmaceutical-related assets and investments in China’s healthcare sector, including an equity stake in Beijing Kangchen Biological Technology Co., Ltd.
Average Trading Volume: 342,883
Technical Sentiment Signal: Hold
Current Market Cap: HK$519.2M
Find detailed analytics on 1011 stock on TipRanks’ Stock Analysis page.